Literature DB >> 10326941

Life-threatening events after theophylline overdose: a 10-year prospective analysis.

M Shannon1.   

Abstract

BACKGROUND: Despite the declining use of theophylline, episodes of intoxication continue to occur, producing seizures, arrhythmias, and death.
OBJECTIVES: To further characterize major toxic effects and to examine the efficacy of existing interventions.
METHODS: We conducted a longitudinal cohort study of patients with theophylline overdose. For a 125-month period, all patients referred to the Massachusetts Poison Control System in Boston with a serum theophylline concentration of 167 micromol/L (> or =30 microg/mL) or more were followed up prospectively. Recommended management by the poison center was uniform and protocol based.
RESULTS: Three hundred fifty-six patients were enrolled. Mean age was 34.5 years (range, 3 days to 98 years). Mean peak serum theophylline concentration was 336 micromol/L (60 microg/mL) (range, 167-1360 micromol/L [30-245 microg/mL]). One hundred sixty-two patients (45.5%) had acute, 144 (40.4%) had chronic, and 50 (14.0%) had acute-on-therapeutic poisoning. Seventy-four patients (20.8%) developed cardiac arrhythmias, and 29 (8.2%) developed seizures. Fifteen patients (4.2%) died, 11 (73%) of whom had chronic overmedication. Arrhythmias were significantly more common after chronic overmedication than after acute intoxication (35% vs. 10%; odds ratio, 4.97; 95% confidence interval, 2.68-9.23; P<.001). Eight percent of patients with chronic overmedication died compared with 2.5% of those with acute intoxication (odds ratio, 3.20; 95% confidence interval, 1.01-10.39; P = .04). There was no significant difference in the rate of major toxic effects (25.9% vs. 30.0%) or death (4.6% vs. 3.7%) among patients referred from 1986 to 1991 and from 1992 to 1996.
CONCLUSIONS: Theophylline intoxication results in substantial morbidity and mortality, particularly in those with chronic overmedication. Treatment strategies fail to improve clinical outcome. With safer alternative options available, the current indications for theophylline should be rigorously evaluated with a goal toward minimal use of this agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10326941     DOI: 10.1001/archinte.159.9.989

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

1.  Demographic and Clinical Characteristics of Theophylline Exposures between 1993 and 2011.

Authors:  Nil Hocaoğlu; Engin Yıldıztepe; Başak Bayram; Burç Aydın; Yeşim Tunçok; Şule Kalkan
Journal:  Balkan Med J       Date:  2014-12-01       Impact factor: 2.021

2.  [Medical therapy of heart and lung diseases. Effects on the respective other organ].

Authors:  S Möhlenkamp; G Weinreich; T Neumann; T Voshaar; H Teschler
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

Review 3.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Tablet splitting of narrow therapeutic index drugs: a nationwide survey in Taiwan.

Authors:  Chia-Lin Chou; Chia-Chen Hsu; Chia-Yu Chou; Tzeng-Ji Chen; Li-Fang Chou; Yueh-Ching Chou
Journal:  Int J Clin Pharm       Date:  2015-09-23

5.  Efficacy of L-carnitine and propranolol in the management of acute theophylline toxicity.

Authors:  Naima A Sherif; Asmaa S El-Banna; Marwan M ElBourini; Nancy O Khalil
Journal:  Toxicol Res (Camb)       Date:  2020-03-11       Impact factor: 3.524

Review 6.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  A case of life-threatening supraventricular tachycardia storm associated with theophylline toxicity.

Authors:  Keishi Ichikawa; Tadashi Wada; Takahiro Nishihara; Masahiro Tsuji; Atsushi Mori; Fumi Yokohama; Daiji Hasegawa; Kenji Kawamoto; Machiko Tanakaya; Yusuke Katyama; Satoru Sakuragi; Hiroshi Ito
Journal:  J Cardiol Cases       Date:  2017-03-06

8.  Allergy and asthma medication use in home-dwelling U.S. older adults.

Authors:  Gaurav S Ajmani; Kristen E Wroblewski; Fuad M Baroody; Robert M Naclerio; Jayant M Pinto
Journal:  Int Forum Allergy Rhinol       Date:  2016-10-03       Impact factor: 3.858

Review 9.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.

Authors:  Preeti Gupta; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.